Predicting HER-2 Expression in Breast Cancer Using MDME-Based T1 and T2 Mapping Combined with DWI

Motivation: HER-2 expression in breast cancer is key for personalized treatment but often requires invasive biopsy. MRI-based quantitative imaging, particularly MDME synthetic T1 and T2 mapping or DWI, may offer a non-invasive, efficient alternative. Goal(s): To evaluate the clinical value of T1, T2, and ADC measurements for predicting HER-2 expression in breast cancer. Approach: In 58 breast cancer patients, MDME rapidly acquired T1 and T2 mappings with multiple contrast images, while DWI provided ADC values. Statistical analysis revealed differences across HER-2 expression levels. Results: T2 values and combined model showed significant predictive power for HER-2 expression, supporting MDME as a non-invasive diagnostic tool. Impact: MDME-based T1 and T2 mappings combined with DWI offers a rapid, non-invasive method for predicting HER-2 expression in breast cancer, potentially reducing the need for biopsy and supporting preoperative decision-making.